Key Highlights

  • Baird Medical Investment Holdings Limited (NASDAQ:BDMD) advanced 20.26% to USD 0.1312 during trading on November 5, 2026, according to published market data, with roughly 108.64 million shares changing hands.
  • A Nasdaq minimum bid price deficiency letter dated November 2, 2026 was disclosed by the company on November 4, 2026.
  • The company has 180 calendar days, through May 3, 2027, to restore a closing bid of USD 1.00 or higher across ten straight Business days.
  • On November 4, 2026, the company stated it was unaware of any material development or hidden cause behind its recent share price fall.

Listing Notice and Management Remarks

Baird Medical disclosed on November 4, 2026 that it had received a Nasdaq letter dated November 2, 2026 under Listing Rule 5550(a)(2), since its bid price had remained under USD 1.00 for 30 straight business days. The shortfall has no immediate impact on trading. The company now has 180 calendar days, until May 3, 2027, to get back into compliance, which means a closing bid of USD 1.00 or more over ten straight business days. A second 180-day window might be granted if it satisfies additional listing criteria and submits written notification of its plan to cure. Management stated it is weighing several options. A separate November 4, 2026 update said the company was tracking its share price and trading and was not aware of any undisclosed reason for the decline.

Company Profile and How Compliance Works

Baird Medical describes itself as a device maker built around microwave ablation performed through minimally invasive techniques. Its flagship system has FDA clearance for soft tissue ablation and is being brought to the United States mainly for benign thyroid nodules. Additional products under development use irreversible electroporation and an AI-guided robotic ablation platform. The typical remedies for a bid price shortfall are a reverse stock split, which reduces the share count and raises the quoted price without altering the company's underlying value, or a lasting rebound in the share price itself. The notice made no reference to a reverse split, and none has been confirmed. Published market data shows trailing diluted EPS of negative USD 0.55.

Risk Factors and Watch Items

At USD 0.1312 and a published market Capitalization near USD 4.2 million, Baird Medical qualifies as a nano-cap stock. The quote sits far under the USD 1.00 level, so a rebound without a reverse split would Demand a gain of more than sevenfold, a plain calculation using those two published figures. A handful of trades can swing the price, spreads may be wide and quoted moves can reverse. Volume of about 108.64 million shares is roughly five times the typical level, pointing to intense speculative trading rather than any shift in the fundamentals. A reverse split, dilutive financing or a miss on the May 3, 2027 deadline could each follow. Keep an eye out for company filings on a compliance plan and any Shareholder vote.

Where Things Stand

The jump at Baird Medical Investment Holdings Limited (NASDAQ:BDMD) does not reflect better fundamentals: the session included a Nasdaq deficiency notice and a statement that management was unaware of any cause for the prior decline. A 20.26% advance from a price near USD 0.13 is modest in dollar terms and could easily fade. The central issue is whether the company fixes the bid price gap by May 3, 2027, most probably via a reverse split. Subsequent filings on its compliance strategy, financing and the United States thyroid rollout are the next catalysts.